Anne Erickson

Ms. Erickson has served as Savara’s Chief Business and Corporate Affairs Officer since February 2026 and is responsible for the Investor Relations/Corporate Affairs, Medical Affairs, Advocacy Relations & Patient Engagement, and Project Management teams and leads corporate strategy projects. Since joining the company in October 2018, Ms. Erickson has held roles of increasing responsibility, including Chief Business Officer, SVP of Global Business Operations, Chief of Staff, and Head of Investor Relations and Corporate Communications. Further, she led the Clinical Operations Team for the IMPALA-2 trial (from study start-up through the double-blind period of the trial) and was also Interim Head of Quality Assurance. Prior to Savara, Ms. Erickson has held leadership roles within corporate, consulting, and agency settings at various companies, including Mirati Therapeutics, Halozyme, Pfizer, and Ogilvy.